Baribeau, Danielle A.
Dupuis, Annie
Paton, Tara A.
Scherer, Stephen W.
Schachar, Russell J.
Arnold, Paul D.
Szatmari, Peter
Nicolson, Rob
Georgiades, Stelios
Crosbie, Jennifer
Brian, Jessica
Iaboni, Alana
Lerch, Jason
Anagnostou, Evdokia
Article History
Received: 26 April 2017
Accepted: 15 August 2017
First Online: 14 September 2017
Competing Interests
: Dr. Schachar has consulted to Highland Therapeutics, Eli Lilly and Co., and Purdue Pharma. He has commercial interest in a cognitive rehabilitation software company, ‘eHave.’ Dr. Arnold holds a patent for ‘SLCIAI Marker for Anxiety Disorder’ (granted May 6, 2008). Dr. Szatmari has received royalties from Guilford Press. Dr. Anagnostou has served as a consultant to Roche. She has received grant funding from SanofiCanada and SynpapDx. She holds a provisional patent for the device, ‘Anxiety Meter’. She has received royalties from APPI and Springer. Dr. Scherer is an academic scientific consultant advising or is in licensing arrangements with Athena, Diagnostics, King Abdulaziz University Lineagen, Deep Genomics and Population Diagnostics. He also holds the CIHR-GlaxoSmithKline Endowed Chair in Genome Sciences at the Hospital for Sick Children and University of Toronto. Drs Baribeau, Iaboni, Dupuis, Crosbie, McGinn, Brian, Nicolson, Georgiades, Paton and Lerch report no biomedical financial interests or potential conflicts of interest.